Navigation Links
Bioness Initiates Study of Neuromodulation System for Chronic Peripheral Nerve Pain
Date:4/9/2012

VALENCIA, Calif., April 9, 2012 /PRNewswire/ -- Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter™ Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States. About 20 million individuals in the United States suffer from chronic peripheral nerve pain, and current treatments include non-localized therapies such as spinal cord stimulation and the use of systemic pain medication.

"Chronic peripheral nerve pain can have a dramatic impact on a patient's quality of life, and historically we have had few treatment options other than the use of pharmaceutical therapy – most often narcotics, which affect the whole body and have many undesirable side-effects," said Timothy Deer, MD, the study's medical monitor and pain management specialist at The Center for Pain Relief at Saint Francis Hospital in Charleston, West Virginia. "The StimRouter could potentially provide - for the first time - a non-pharmaceutical treatment option that can be targeted directly to the pain site for more focused pain relief. The results of this study could have a significant impact on the way we treat patients with peripheral nerve pain."

The StimRouter System is designed to relieve chronic neuropathic pain of peripheral origin. The device consists of an implanted lead that delivers low-level electrical impulses directly to the nerve that carries the pain signal. The External Pulse Transmitter (EPT), worn outside the body, sends electrical signals through the skin to the implanted lead. The EPT has the capability of storing stimulation programs to provide patients with a variety of treatment options depending on their activity or level of pain.

"At Bioness, we have always been dedicated to developing technologies that help patients improve their quality of life despite debilitating conditions," said Thomas G. Fogarty, President and CEO of Bioness. "The results of this study will help improve our understanding of how to most effectively treat chronic peripheral pain while improving patient care, potentially enabling us to help a greater number of patients."

The study, "Prospective, Multi-Center, Randomized, Double-Blinded, Partial Crossover Study to Assess the Safety and Efficacy of the Bioness® StimRouter™ Neuromodulation System in the Treatment for Patients with Chronic Pain of Peripheral Nerve Origin," is expected to last for 30 months, with each study participant receiving treatment and evaluation for a total of 13 months. The study will evaluate the effect of the system on patients' overall pain, as well as changes in pain medication, quality of life, patient impression of improvement with treatment, change in worst pain, interference of pain with physical and emotional functioning, patient satisfaction and long-term safety.

For more information about this study contact Cheryl Doriot, Clinical Study Manager, at Bioness at Cheryl.Doriot@bioness.com.

About Bioness Inc.
Bioness provides neuromodulation technologies that help improve lives and restore function for those living with neurological deficits and peripheral pain. The company develops, manufactures and markets innovative neuromodulation products that help individuals with central nervous system disorders such as stroke, multiple sclerosis, spinal cord injury and traumatic brain injury regain movement in affected limbs. The L300® Foot Drop System, L300® Plus System, H200® Hand Rehabilitation System, and H200® Wireless Hand Rehabilitation System are cleared for use by the Food and Drug Administration and are designed to help patients achieve new levels of physical independence and productivity. Individual results vary. Consult with a qualified physician to find out if these products are right for you. Additional information about Bioness can be found at www.bioness.com.

L300®, L300® Plus, H200®, and Bioness® are trademarks of Bioness Inc. | www.bioness.com | Rx Only

Media Contact:

Wendy Ryan/Courtney Conery
Schwartz MSL
781-684-0770
bioness@SchwartzMSL.com


'/>"/>
SOURCE Bioness Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study
2. Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders
3. Bioness Inc Announces Availability of L300 Plus System
4. Bioness Inc. Receives FDA Clearance of Its NESS L300 Plus System
5. OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial
6. Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
7. EntreMed Initiates Plans for China Office
8. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
9. Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
10. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
11. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):